中重度银屑病与化脓性汗腺炎患者健康相关生活质量负担差异比较
本研究基于5项临床试验的基线数据,采用加权平均值比较中重度化脓性汗腺炎(HS)与银屑病患者的健康相关生活质量(HRQoL)。结果显示HS患者在疼痛VAS、皮肤病生活质量指数、EuroQOL 5D VAS、总工作生产力损害及SF-36各维度上均显著差于银屑病患者,提示HS的HRQoL负担更高。
要点
- 中重度HS患者的HRQoL损害显著高于银屑病患者。
- HS患者疼痛VAS评分54.3 vs 银屑病36.1(P<.0001)。
- HS患者DLQI 15.3 vs 银屑病11.3(P<.0001),SF-36各维度均更低。
核心结论
- 中重度HS患者的健康相关生活质量负担高于中重度银屑病患者。
研究设计与样本
- 基于5项临床试验的基线HRQoL数据,采用加权平均值比较HS与银屑病人群。
主要发现
- HS患者疼痛VAS评分为54.3,银屑病患者为36.1(P<.0001)。
- HS患者DLQI评分为15.3,银屑病患者为11.3(P<.0001)。
- HS患者EuroQOL 5D VAS评分为58.8,银屑病患者为50.8(P<.0002)。
- HS患者总工作生产力损害评分为35.4,银屑病患者为18.2。
- HS患者SF-36生理维度评分为39.6 vs 银屑病49.0,心理维度为41.5 vs 47.5(均P<.0001)。
临床怎么用
- 临床评估中应重视中重度HS患者的生活质量损害和疼痛负担。
- HS的治疗决策需考虑其高于银屑病的HRQoL负担,推动更有效治疗方案的开发。
局限性
- 分析使用已发表的汇总数据而非患者个体数据,比较的是加权合并平均值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Psoriasis and hidradenitis suppurativa (HS) exhibit distinct clinical features, but no studies have directly compared the health-related quality of life (HRQoL) in patients with moderate-to-severe manifestations of these conditions. OBJECTIVE: To determine which disease is associated with more severe HRQoL impairment. METHODS: Weighted averages of each of the following baseline HRQoL measures were determined and compared between HS and psoriasis populations from 5 clinical trials: Visual Analog Scale (VAS) for pain, Total Work Productivity Impairment, Dermatology Life Quality Index; EuroQOL 5D VAS, and Short Form-36 Health Survey. RESULTS: Compared with patients with psoriasis, patients with HS reported higher scores for VAS-pain (54.3 vs 36.1 [P < .0001]), Dermatology Life Quality Index (15.3 vs 11.3 [P < .0001]), EuroQOL 5D VAS (58.8 vs 50.8 [P < .0002]), and Total Work Productivity Impairment (35.4 vs 18.2). Patients with HS had lower Short Form-36 Health Survey scores than did patients with psoriasis (physical, 39.6 vs 49.0; mental, 41.5 vs 47.5 [both P < .0001]). LIMITATIONS: This analysis was performed using published summary data rather than patient-level data, and weighted pooled averages were compared. CONCLUSIONS: Patients with HS have a higher HRQoL burden than patients with psoriasis. This study clearly documents the needs of patients with HS and the potential impact of medical, scientific, and societal consensus for the development of more effective HS treatments.
引用
- Hamzavi IH, Sundaram M, Nicholson C, et al. Uncovering burden disparity: A comparative analysis of the impact of moderate-to-severe psoriasis and hidradenitis suppurativa. J Am Acad Dermatol. 2017. PMID: 28917381. doi:10.1016/j.jaad.2017.07.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。